PMC9513037_01
BCR::ABL1 transcript levels during the treatment with each TKIs.
fonc-12-1012268-g001.jpg
PMC9513037_01_fonc-12-1012268-g001.jpg
f1
However, after 6 months from imatinib start molecular evaluation showed a slight increase in BCR::ABL1 transcript level till to 0.7924% IS, thus defining a warning response according to 2020 ELN recommendations ( Figure 1 ).